z-logo
Premium
Evaluation of paternal lymphocyte immunotherapy and potential biomarker mixed lymphocyte reaction‐blocking factor in an Argentinian cohort of women with unexplained recurrent spontaneous abortion and unexplained infertility
Author(s) -
Fainboim Leonardo,
Belén Santiago,
González Verónica,
Fernández Pablo
Publication year - 2021
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.13422
Subject(s) - medicine , live birth , abortion , pregnancy , gynecology , obstetrics , unexplained infertility , lymphocyte , gestation , infertility , cohort , immunology , biology , genetics
Problem Analyze the effect of paternal immunotherapy treatment (PIT) in primary and secondary unexplained recurrent spontaneous abortion (URSA) and unexplained infertility (UI). Methods of Study A retrospective study analyzed a two‐year follow‐up between the generation of MLR‐Bfs after PIT treatment (or controls first consultation) and a live birth. Recruited patients included primary URSA with two or more miscarriages at <12 weeks gestation, secondary URSA with previous live birth before two or more miscarriages, and UI with inability to conceive after 2 years of regular unprotected intercourse or in vitro fertilizations (IVF). PIT treated were compared with untreated controls. Results Primary URSA: live birth was 241/416 (58%) versus 64/282 (23%) controls ( p  < .0001). Up to age 35, success was 158/217 (73%) and 37/144 (26%) controls ( p  < .0001). With 3 or more previous URSA, success was 90/135 (67%) versus 17/79 (22%) controls ( p  < .0001). Between ages 36 and 40, success was 69/147(47%) versus 22/98 (22%) controls ( p  < .0003), with 3 or more previous URSA live birth was 45/95 (47%) versus 6/46 (13%) controls ( p  < .0001). In UI, live birth was 99/298 (33%) versus 54/263 (21%) in controls ( p  < .0009) that increased under age 35 to 53/116 (46%) in treated versus 26/101 (26%) controls ( p  < .0056). In PIT treated, IVF success required a median of 1 (1.37 ± 0.67) versus a median of 3 IVF procedures (2.75 ± 0.84) in controls. Conclusion PIT is a successful treatment for primary and secondary URSA, and UI. PIT reduced the number of IVF required for achieving pregnancy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here